Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study

doi:10.1002/gcc.23043

	Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study
	Wang, Wenxian 1,2; Gu, Xiaodong 1,2; Si, Jinfei 1,2; Pu, Xingxiang 3; Wang, Liping 4; Chen, Huafei 5; Xu, Chunwei 6; Zhang, Xiaoyan 7; Yuan, Hongling 7; Lou, Guangyuan 1,2
刊名	GENES CHROMOSOMES & CANCER
	2022-04-23
关键词	BRAF mutation immune checkpoint inhibitors non-small cell lung cancer PD-L1 targeted therapy
ISSN号	1045-2257
DOI	10.1002/gcc.23043
通讯作者	Zhang, Gu(zjch1971@163.com) ; Song, Zhengbo(zheng_bo_song@163.com)
英文摘要	The incidence of primary and acquired BRAF mutations is low in non-small cell lung cancer (NSCLC), with limited demographic and treatment outcome data available for this patient population. We evaluated lung cancer samples with programmed cell death ligand 1 (PD-L1) information extracted from 12 051 cases (cohort A) of lung cancer from OncoPanscan (TM)-based sequencing of tissue (Genetron Health) and conducted retrospective multicenter data analysis using the database of Zhejiang Cancer Hospital and four other centers (cohort B, including 73 primary BRAF mutation and 14 acquired BRAF mutation cases) to compare treatment outcomes of patient groups with primary and acquired BRAF mutations. In cohort A, after propensity score analysis, 165 samples of NSCLC with BRAF mutations were screened along with 165 paired non-BRAF mutation samples. We observed no significant differences in the proportion of samples with >= 1% PD-L1 between BRAF and non-BRAF mutant groups. The median progression-free survival (mPFS) period in 13 patients with primary BRAF mutations receiving BRAF tyrosine kinase inhibitors (BRAF-TKIs) was 7.0 months. The group with primary BRAF mutations receiving immune checkpoint inhibitor (ICI) combination chemotherapy had better PFS than those administered ICI monotherapy (14.77 months vs. 5.0 months, p = 0.025) and similar results were obtained for OS (unreached vs. 20.3 months, p = 0.013). For acquired BRAF mutations, mPFS of BRAF-TKI, ICI-based, and chemotherapy-based regimens were 3.8, 1.5, and 1.9 months, respectively. Therefore, for patients with the primary BRAF V600E mutation, targeted therapy or immunochemotherapy could serve as effective treatment choices, while for those with acquired BRAF V600E, targeted drug therapy may remain the preferred solution in China.
资助项目	Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation ; Xisike-Hanson Cancer Research Foundation ; Zhejiang Chinese Medical Science and Technology Foundation ; Cancer Research Foundation[HS2020-5] ; Cancer Research Foundation[HS2019-20] ; Cancer Research Foundation[2021ZQ013]
WOS关键词	DABRAFENIB PLUS TRAMETINIB ; DURABLE CLINICAL-RESPONSE ; OPEN-LABEL ; MUTATIONS ; NSCLC ; OSIMERTINIB ; CRIZOTINIB ; DOCETAXEL ; MECHANISM ; SURVIVAL
WOS研究方向	Oncology ; Genetics & Heredity
语种	英语
出版者	WILEY
WOS记录号	WOS:000785909100001
资助机构	Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation ; Xisike-Hanson Cancer Research Foundation ; Zhejiang Chinese Medical Science and Technology Foundation ; Cancer Research Foundation
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128589]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Gu; Song, Zhengbo
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 3.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol, Changsha, Peoples R China 4.Baotou Canc Hosp, Dept Oncol, Baotou, Inner Mongolia, Peoples R China 5.Zhejiang Rongjun Hosp, Dept Thorac Dis Ctr, Jiaxing, Zhejiang, Peoples R China 6.Nanjing Univ, Affiliated Jinling Hosp, Med Sch, Dept Resp Med, Nanjing, Jiangsu, Peoples R China 7.Genetron Hlth Beijing Technol Co Ltd, Dept Translat Med, Beijing, Peoples R China 8.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Pathol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Wenxian,Gu, Xiaodong,Si, Jinfei,et al. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study[J]. GENES CHROMOSOMES & CANCER,2022.
APA	Wang, Wenxian.,Gu, Xiaodong.,Si, Jinfei.,Pu, Xingxiang.,Wang, Liping.,...&Song, Zhengbo.(2022).Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.GENES CHROMOSOMES & CANCER.
MLA	Wang, Wenxian,et al."Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study".GENES CHROMOSOMES & CANCER (2022).